Sunmax Biotechnology Co Ltd
4728.TWO
| Exchange: | TWO |
| Currency | New Taiwan Dollar |
| ISIN: | TW0004728001 |
| Primary Ticker: | 4728.TWO |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Biotechnology |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Biotechnology |
| Gic Sub Industry: | Biotechnology |
| Description: | Sunmax Biotechnology Co., Ltd., a biomedical company, develops, manufactures, and markets collagen-based medical devices in Taiwan and Mainland China. The company offers dermal fillers, including Sunmax FACIALGAIN collagen implant with lidocaine, Sunmax collagen implant I-Plus, Sumax collagen implant I, Sunmax FACIALGAIN collagen implant 1-Plus with lidocaine for the correction of facial defects, such as the fill up of wrinkles; and Porcogen, a sterile purified collagen solution for medical device, tissue engineering, and research purposes. It also provides Sunmax collagen dental bone graft, Sunmax collagen dental membrane, and Sunmax dental bone graft granules, which are used in the augmentation or reconstructive treatment of the alveolar ridge. In addition, the company offers Sunmax collagen bone graft matrix that provides a bone void filler that is resorbed and replaced with bone during the healing process; and skincare products comprising Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and Sunmax collagen skincare that are used as aftercare of dermal filler treatment. Sunmax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Tainan City, Taiwan. |
| Address: | No. 10, Lane 31, Huandong Road, Tainan City, Taiwan, 744 |
| Website: | https://www.sunmaxbiotech.com |
| Updated On: | 2024-11-04 |
Highlights
| Market Capitalization: | 14868399104 |
| Market Capitalization Mln: | 14868.39 |
| EBITDA: | 994033984 |
| PE Ratio: | 20.91 |
| Book Value: | 21.87 |
| Dividend Share: | 11 |
| Dividend Yield: | 0.04 |
| Earnings Share: | 13.05 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.40 |
| Operating Margin TTM: | 0.55 |
| Return On Assets TTM: | 0.25 |
| Return On Equity TTM: | 0.62 |
| Revenue TTM: | 1759762944 |
| Revenue Per Share TTM: | 32.31 |
| Quarterly Revenue Growth YOY: | 0.08 |
| Gross Profit TTM: | 894447000 |
| Diluted Eps TTM: | 13.05 |
| Quarterly Earnings Growth YOY: | 0.26 |
Valuation
| Trailing PE: | 20.91 |
| Price Sales TTM: | 8.44 |
| Price Book MRQ: | 12.47 |
| Enterprise Value: | 13865077760 |
| Enterprise Value Revenue: | 7.87 |
| Enterprise Value Ebitda: | 12.90 |
Shares
| Shares Outstanding: | 54463000 |
| Shares Float: | 34100918 |
| Percent Insiders: | 40.40 |
| Percent Institutions: | 6.95 |
Technicals
| Beta: | 0.27 |
| 52 Week High: | 337.39 |
| 52 Week Low: | 182.19 |
| 50 Day MA: | 271.07 |
| 200 Day MA: | 256.61 |
Splits & Dividends
| Forward Annual Dividend Rate: | 11 |
| Forward Annual Dividend Yield: | 0.04 |
| Payout Ratio: | 0.72 |
| Ex Dividend Date: | 2024-07-17 |
Earnings
| Report Date: | 2025-06-27 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | TWD |